Banking

Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating

Cel-Sci (CVM) saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 78 to 81.




X



When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock’s price performance over the trailing 52 weeks matches up against that of all other stocks.

Decades of market research reveals that the top-performing stocks tend to have an RS Rating of over 80 in the early stages of their moves.


See How IBD Helps You Make More Money In Stocks


Cel-Sci stock is now considered extended and out of buy range after clearing an 18.10 buy point in a third-stage consolidation back in January. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips. Also, check out “Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.”

 

The biotech firm posted -12% earnings growth in its most recent report, while sales growth came in at -100%.

The company holds the No. 186 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads (BNTX) and Vanda Pharmaceuticals (VNDA) are also among the group’s highest-rated stocks.  For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”

YOU MIGHT ALSO LIKE:

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

 

Most Related Links :
todayuknews Governmental News Finance News

Source link

Back to top button
Native News Post